GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2010

Esperion Taps TransGenRx for Protein Production to Support HDL-Related Research

  • TransGenRx has agreed to produce protein-based therapeutics for Esperion Therapeutics to use in its research efforts targeting HDL therapies for the treatment of cardio-metabolic disease. TransGenRx will coordinate manufacturing for a range of research needs using a its expression system.

    TransGenRx uses a high-expressing avian cell line combined with a patented vector system. The company says that it is able to develop custom proteins at reduced costs to meet a wide range of specifications. The company's core technology involves the targeted integration of a desired gene sequence into virtually any animal or cell culture system and the controlled expression of that sequence to achieve a desired outcome.

    “While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies,” notes Roger Newton, Ph.D., president and CEO of Esperion. “By working with the outstanding research and technology team at TransGenRx, we are positioned to access one of the most advanced, cost-effective protein-expression technologies in the world to supply the protein-based therapies we will use in our research.”

    Esperion’s pipeline includes therapies designed to mimic or enhance the function of HDL in managing and removing cholesterol and other lipids from atherosclerotic plaques. The firm has initiated preclinical and clinical research related to a variety of pathways for better lipid regulation.

    On June 14, Esperion established a research agreement with the Cleveland Clinic Foundation to advance research involving HDL mimetics and other protein-based therapies to treat cardiovascular disease.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »